TY - JOUR AU - Parfrey, P. S. AU - Lauve, M. AU - Latremouille-Viau, D. AU - Lefebvre, P. PY - 2009 DA - 2009// TI - Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis JO - Clin J Am Soc Nephrol VL - 4 UR - https://doi.org/10.2215/CJN.02730608 DO - 10.2215/CJN.02730608 ID - Parfrey2009 ER - TY - JOUR AU - Covic, A. AU - Nistor, I. AU - Donciu, M. D. AU - Dumea, R. AU - Bolignano, D. AU - Goldsmith, D. PY - 2014 DA - 2014// TI - Erythropoiesis-stimulating agents (ESA) for preventing the progression of chronic kidney disease: a meta-analysis of 19 studies JO - Am J Nephrol VL - 40 UR - https://doi.org/10.1159/000366025 DO - 10.1159/000366025 ID - Covic2014 ER - TY - JOUR AU - Stenvinkel, P. AU - Heimburger, O. AU - Paultre, F. AU - Diczfalusy, U. AU - Wang, T. AU - Berglund, L. PY - 1999 DA - 1999// TI - Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure JO - Kidney Int VL - 55 UR - https://doi.org/10.1046/j.1523-1755.1999.00422.x DO - 10.1046/j.1523-1755.1999.00422.x ID - Stenvinkel1999 ER - TY - JOUR AU - Stenvinkel, P. PY - 2001 DA - 2001// TI - Inflammatory and atherosclerotic interactions in the depleted uremic patient JO - Blood Purif VL - 19 UR - https://doi.org/10.1159/000014479 DO - 10.1159/000014479 ID - Stenvinkel2001 ER - TY - JOUR AU - Besarab, A. AU - Chernyavskaya, E. AU - Motylev, I. AU - Shutov, E. AU - Kumbar, L. M. AU - Gurevich, K. PY - 2016 DA - 2016// TI - Roxadustat (FG-4592): correction of anemia in incident dialysis patients JO - J Am Soc Nephrol VL - 27 UR - https://doi.org/10.1681/ASN.2015030241 DO - 10.1681/ASN.2015030241 ID - Besarab2016 ER - TY - JOUR AU - Provenzano, R. AU - Besarab, A. AU - Wright, S. AU - Dua, S. AU - Zeig, S. AU - Nguyen, P. PY - 2016 DA - 2016// TI - Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose ranging, safety and exploratory efficacy study JO - Am J Kidney Dis VL - 67 UR - https://doi.org/10.1053/j.ajkd.2015.12.020 DO - 10.1053/j.ajkd.2015.12.020 ID - Provenzano2016 ER - TY - JOUR AU - Chen, N. AU - Qian, J. AU - Chen, J. AU - Yu, X. AU - Mei, C. AU - Hao, C. PY - 2017 DA - 2017// TI - Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China JO - Nephrol Dial Transplant VL - 32 UR - https://doi.org/10.1093/ndt/gfx011 DO - 10.1093/ndt/gfx011 ID - Chen2017 ER - TY - JOUR AU - Holdstock, L. AU - Meadowcroft, A. M. AU - Maier, R. AU - Johnson, B. M. AU - Jones, D. AU - Rastogi, A. PY - 2016 DA - 2016// TI - Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia JO - J Am Soc Nephrol VL - 27 UR - https://doi.org/10.1681/ASN.2014111139 DO - 10.1681/ASN.2014111139 ID - Holdstock2016 ER - TY - JOUR AU - Brigandi, R. A. AU - Johnson, B. AU - Oei, C. AU - Westerman, M. AU - Olbina, G. AU - Zoysa, J. PY - 2016 DA - 2016// TI - A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial JO - Am J Kidney Dis VL - 67 UR - https://doi.org/10.1053/j.ajkd.2015.11.021 DO - 10.1053/j.ajkd.2015.11.021 ID - Brigandi2016 ER - TY - JOUR AU - Akizawa, T. AU - Tsubakihara, Y. AU - Nangaku, M. AU - Endo, Y. AU - Nakajima, H. AU - Kohno, T. PY - 2017 DA - 2017// TI - Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects JO - Am J Nephrol VL - 45 UR - https://doi.org/10.1159/000454818 DO - 10.1159/000454818 ID - Akizawa2017 ER - TY - JOUR AU - Meadowcroft, A. M. AU - Cizman, B. AU - Holdstock, L. AU - Biswas, N. AU - Johnson, B. M. AU - Jones, D. PY - 2019 DA - 2019// TI - Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis JO - Clin Kidney J VL - 12 UR - https://doi.org/10.1093/ckj/sfy014 DO - 10.1093/ckj/sfy014 ID - Meadowcroft2019 ER - TY - JOUR AU - Haase, V. H. AU - Chertow, G. M. AU - Block, G. A. AU - Pergola, P. E. AU - DeGoma, E. M. AU - Khawaja, Z. PY - 2019 DA - 2019// TI - Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents JO - Nephrol Dial Transplant VL - 34 UR - https://doi.org/10.1093/ndt/gfy055 DO - 10.1093/ndt/gfy055 ID - Haase2019 ER - TY - JOUR AU - Macdougall, I. C. AU - Akizawa, T. AU - Berns, J. S. AU - Bernhardt, T. AU - Krueger, T. PY - 2019 DA - 2019// TI - Effects of molidustat in the treatment of anemia in CKD JO - Clin J Am Soc Nephrol VL - 14 UR - https://doi.org/10.2215/CJN.02510218 DO - 10.2215/CJN.02510218 ID - Macdougall2019 ER - TY - JOUR AU - Besarab, A. AU - Provenzano, R. AU - Hertel, J. AU - Zabaneh, R. AU - Klaus, S. J. AU - Lee, T. PY - 2015 DA - 2015// TI - Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in non-dialysis dependent chronic kidney disease (NDD-CKD) patients JO - Nephrol Dial Transplant VL - 30 UR - https://doi.org/10.1093/ndt/gfv302 DO - 10.1093/ndt/gfv302 ID - Besarab2015 ER - TY - JOUR AU - Provenzano, R. AU - Besarab, A. AU - Sun, C. H. AU - Diamond, S. A. AU - Durham, J. H. AU - Cangiano, J. L. PY - 2016 DA - 2016// TI - Oral hypoxia–inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD JO - Clin J Am Soc Nephrol VL - 11 UR - https://doi.org/10.2215/CJN.06890615 DO - 10.2215/CJN.06890615 ID - Provenzano2016 ER - TY - JOUR AU - Holdstock, L. AU - Cizman, B. AU - Meadowcroft, A. M. AU - Biswas, N. AU - Johnson, B. M. AU - Jones, D. PY - 2019 DA - 2019// TI - Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease JO - Clin Kidney J VL - 12 UR - https://doi.org/10.1093/ckj/sfy013 DO - 10.1093/ckj/sfy013 ID - Holdstock2019 ER - TY - JOUR AU - Pergola, P. E. AU - Spinowitz, B. S. AU - Hartman, C. S. AU - Maroni, B. J. AU - Haase, V. H. PY - 2016 DA - 2016// TI - Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease JO - Kidney Int VL - 90 UR - https://doi.org/10.1016/j.kint.2016.07.019 DO - 10.1016/j.kint.2016.07.019 ID - Pergola2016 ER - TY - JOUR AU - Martin, E. R. AU - Smith, M. T. AU - Maroni, B. J. AU - Zuraw, Q. C. AU - DeGoma, E. M. PY - 2017 DA - 2017// TI - Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease JO - Am J Nephrol VL - 45 UR - https://doi.org/10.1159/000464476 DO - 10.1159/000464476 ID - Martin2017 ER - TY - JOUR AU - Akizawa, T. AU - Nangaku, M. AU - Yamaguchi, T. AU - Arai, M. AU - Koretomo, R. AU - Matsui, A. PY - 2019 DA - 2019// TI - A placebo-controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial JO - Am J Nephrol VL - 49 UR - https://doi.org/10.1159/000496929 DO - 10.1159/000496929 ID - Akizawa2019 ER - TY - JOUR AU - Sender, R. AU - Fuchs, S. AU - Milo, R. PY - 2016 DA - 2016// TI - Revised estimates for the number of human and bacteria cells in the body JO - PLoS Biol VL - 14 UR - https://doi.org/10.1371/journal.pbio.1002533 DO - 10.1371/journal.pbio.1002533 ID - Sender2016 ER - TY - JOUR AU - Yamamoto, H. AU - Nishi, S. AU - Tomo, T. AU - Masakane, I. AU - Saito, K. AU - Nangaku, M. PY - 2017 DA - 2017// TI - 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease JO - Ren Rep Ther VL - 3 ID - Yamamoto2017 ER - TY - JOUR AU - Brannon, E. S. AU - Merrill, A. J. AU - Warren, J. V. AU - Stead, E. A. PY - 1945 DA - 1945// TI - The cardiac output in patients with chronic anemia as measured by the technique of right atrial catheterization JO - J Clin Invest VL - 24 UR - https://doi.org/10.1172/JCI101610 DO - 10.1172/JCI101610 ID - Brannon1945 ER - TY - JOUR AU - Tanaka, T. AU - Eckardt, K. U. PY - 2018 DA - 2018// TI - HIF activation against CVD in CKD: novel treatment opportunities JO - Semin Nephrol VL - 38 UR - https://doi.org/10.1016/j.semnephrol.2018.02.006 DO - 10.1016/j.semnephrol.2018.02.006 ID - Tanaka2018 ER - TY - JOUR AU - Silverberg, D. S. AU - Wexler, D. AU - Iaina, A. PY - 2002 DA - 2002// TI - The importance of anemia and its correction in the management of severe congestive heart failure JO - Eur J Heart Fail. VL - 4 UR - https://doi.org/10.1016/S1388-9842(02)00115-0 DO - 10.1016/S1388-9842(02)00115-0 ID - Silverberg2002 ER - TY - JOUR AU - Ayus, J. C. AU - Go, A. S. AU - Valderrabano, F. AU - Verde, E. AU - Vinuesa, S. G. AU - Achinger, S. G. PY - 2005 DA - 2005// TI - Spanish Group for the study of the anemia and left ventricular hypertrophy in pre-dialysis patients. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL JO - Kidney Int VL - 68 UR - https://doi.org/10.1111/j.1523-1755.2005.00458.x DO - 10.1111/j.1523-1755.2005.00458.x ID - Ayus2005 ER - TY - JOUR AU - Akaishi, M. AU - Hiroe, M. AU - Hada, Y. AU - Suzuki, M. AU - Tsubakihara, Y. AU - Akizawa, T. PY - 2013 DA - 2013// TI - Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease JO - J Cardiol VL - 62 UR - https://doi.org/10.1016/j.jjcc.2013.04.008 DO - 10.1016/j.jjcc.2013.04.008 ID - Akaishi2013 ER - TY - JOUR AU - Kuriyama, S. AU - Tomonari, H. AU - Yoshida, H. AU - Hashimoto, T. AU - Kawaguchi, Y. AU - Sakai, O. PY - 1997 DA - 1997// TI - Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients JO - Nephron VL - 77 UR - https://doi.org/10.1159/000190270 DO - 10.1159/000190270 ID - Kuriyama1997 ER - TY - JOUR AU - Gouva, C. AU - Nikolopoulos, P. AU - Ioannidis, J. P. AU - Siamopoulos, K. C. PY - 2004 DA - 2004// TI - Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC JO - Kidney Int VL - 66 UR - https://doi.org/10.1111/j.1523-1755.2004.00797.x DO - 10.1111/j.1523-1755.2004.00797.x ID - Gouva2004 ER - TY - JOUR AU - Tsubakihara, Y. AU - Akizawa, T. AU - Iwasaki, M. AU - Shimazaki, R. PY - 2015 DA - 2015// TI - High hemoglobin levels maintained by an erythropoiesis-stimulating agent improve renal survival in patients with severe renal impairment JO - Ther Apher Dial VL - 19 UR - https://doi.org/10.1111/1744-9987.12308 DO - 10.1111/1744-9987.12308 ID - Tsubakihara2015 ER - TY - JOUR AU - Akizawa, T. AU - Tsubakihara, Y. AU - Hirakata, H. AU - Watanabe, Y. AU - Hase, H. AU - Nishi, S. PY - 2016 DA - 2016// TI - A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study JO - Clin Exp Nephrol VL - 20 UR - https://doi.org/10.1007/s10157-015-1225-9 DO - 10.1007/s10157-015-1225-9 ID - Akizawa2016 ER - TY - STD TI - Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, et al. Darbepoetin alfa in patients with advanced CKD without diabetes: randomized, controlled trial. Clin J Am Soc Nephrol. 2020. https://doi.org/10.2215/CJN.08900719 [Epub ahead of print]. ID - ref31 ER - TY - JOUR AU - Besarab, A. AU - Bolton, W. K. AU - Browne, J. K. AU - Egrie, J. C. AU - Nissenson, A. R. AU - Okamoto, D. M. PY - 1998 DA - 1998// TI - The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin JO - N Engl J Med VL - 339 UR - https://doi.org/10.1056/NEJM199808273390903 DO - 10.1056/NEJM199808273390903 ID - Besarab1998 ER - TY - JOUR AU - Drüeke, T. B. AU - Locatelli, F. AU - Clyne, N. AU - Eckardt, K. U. AU - Macdougall, I. C. AU - Tsakiris, D. PY - 2006 DA - 2006// TI - Normalization of hemoglobin level in patients with chronic kidney disease and anemia JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa062276 DO - 10.1056/NEJMoa062276 ID - Drüeke2006 ER - TY - JOUR AU - Singh, A. K. AU - Szczech, L. AU - Tang, K. L. AU - Barnhart, H. AU - Sapp, S. AU - Wolfson, M. PY - 2006 DA - 2006// TI - Correction of anemia with epoetin alfa in chronic kidney disease JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa065485 DO - 10.1056/NEJMoa065485 ID - Singh2006 ER - TY - JOUR AU - Pfeffer, M. A. AU - Burdmann, E. A. AU - Chen, C. Y. AU - Cooper, M. E. AU - Zeeuw, D. AU - Eckardt, K. U. PY - 2009 DA - 2009// TI - A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0907845 DO - 10.1056/NEJMoa0907845 ID - Pfeffer2009 ER - TY - JOUR AU - Swedberg, K. AU - Young, J. B. AU - Anand, I. S. AU - Cheng, S. AU - Desai, A. S. AU - Diaz, R. PY - 2013 DA - 2013// TI - Treatment of anemia with darbepoetin alfa in systolic heart failure JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1214865 DO - 10.1056/NEJMoa1214865 ID - Swedberg2013 ER - TY - JOUR AU - Kuragano, T. AU - Kitamura, K. AU - Matsumura, O. AU - Matsuda, A. AU - Hara, T. AU - Kiyomoto, H. PY - 2016 DA - 2016// TI - ESA hyporesponsiveness is associated with adverse events in maintenance hemodialysis patients, but not with iron storage JO - PloS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0147328 DO - 10.1371/journal.pone.0147328 ID - Kuragano2016 ER - TY - JOUR AU - McCullough, P. A. AU - Barnhart, H. X. AU - Inrig, J. K. AU - Reddan, D. AU - Sapp, S. AU - Patel, U. D. PY - 2013 DA - 2013// TI - Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease JO - Am J Nephrol VL - 37 UR - https://doi.org/10.1159/000351175 DO - 10.1159/000351175 ID - McCullough2013 ER - TY - JOUR AU - Kanbay, M. AU - Perazella, M. A. AU - Kasapoglu, B. AU - Koroglu, M. AU - Covic, A. PY - 2010 DA - 2010// TI - Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management JO - Blood Purif VL - 29 UR - https://doi.org/10.1159/000245041 DO - 10.1159/000245041 ID - Kanbay2010 ER - TY - JOUR PY - 2012 DA - 2012// TI - KDIGO Practice Guideline for anemia in chronic kidney disease JO - Kidney Int VL - suppl 2 ID - ref40 ER - TY - JOUR AU - Yamamoto, H. AU - Nishi, S. AU - Tomo, T. AU - Masakane, I. AU - Saito, K. AU - Nangaku, M. PY - 2017 DA - 2017// TI - 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease JO - Ren Rep Ther VL - 3 ID - Yamamoto2017 ER - TY - JOUR AU - McFarlane, S. I. AU - Chen, S. C. AU - Whaley-Connell, A. T. AU - Sowers, J. R. AU - Vassalotti, J. A. AU - Salifu, M. O. PY - 2008 DA - 2008// TI - Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004 JO - Am J Kidney Dis VL - 51 UR - https://doi.org/10.1053/j.ajkd.2007.12.019 DO - 10.1053/j.ajkd.2007.12.019 ID - McFarlane2008 ER - TY - JOUR AU - Go, A. S. AU - Chertow, G. M. AU - Fan, D. AU - McCulloch, C. E. AU - Hsu, C. Y. PY - 2004 DA - 2004// TI - Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization JO - N Engl J Med VL - 351 UR - https://doi.org/10.1056/NEJMoa041031 DO - 10.1056/NEJMoa041031 ID - Go2004 ER - TY - JOUR AU - Himmelfarb, J. AU - Stenvinkel, P. AU - Ikizler, T. A. AU - Hakim, R. M. PY - 2002 DA - 2002// TI - The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia JO - Kidney Int VL - 62 UR - https://doi.org/10.1046/j.1523-1755.2002.00600.x DO - 10.1046/j.1523-1755.2002.00600.x ID - Himmelfarb2002 ER - TY - JOUR AU - Otaki, Y. AU - Nakanishi, N. AU - Hasuike, Y. AU - Moriguchi, M. AU - Nanami, Y. AU - Hama, M. PY - 2004 DA - 2004// TI - Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis JO - Am J Kidney Dis VL - 43 UR - https://doi.org/10.1053/j.ajkd.2004.02.016 DO - 10.1053/j.ajkd.2004.02.016 ID - Otaki2004 ER - TY - JOUR AU - Nakanishi, T. AU - Kuragano, T. AU - Nanami, M. AU - Nagasawa, Y. AU - Nanami, M. AU - Hasuike, Y. PY - 2019 DA - 2019// TI - Misdistribution of iron and oxidative stress in chronic kidney disease JO - Free Rad Biol Med VL - 133 UR - https://doi.org/10.1016/j.freeradbiomed.2018.06.025 DO - 10.1016/j.freeradbiomed.2018.06.025 ID - Nakanishi2019 ER - TY - JOUR AU - Honda, H. AU - Kobayashi, Y. AU - Onuma, S. AU - Shibagaki, K. AU - Yuza, T. AU - Hirao, K. PY - 2016 DA - 2016// TI - Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis JO - PloS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0151601 DO - 10.1371/journal.pone.0151601 ID - Honda2016 ER - TY - JOUR AU - Honda, H. AU - Hosaka, N. AU - Ganz, T. AU - Shibata, T. PY - 2019 DA - 2019// TI - Iron metabolism in chronic kidney disease patients. Nakanishi T, Kuragano T (eds): CKD-Associated Complications: Progress in the Last Half Century JO - Contrib Nephrol VL - 198 UR - https://doi.org/10.1159/000496369 DO - 10.1159/000496369 ID - Honda2019 ER - TY - JOUR AU - Peyssonnaux, C. AU - Zinkernagel, A. S. AU - Schuepbach, R. A. AU - Rankin, E. AU - Vaulont, S. AU - Haase, V. H. PY - 2007 DA - 2007// TI - Regulation of iron homeostasis by the hypoxia inducible transcription factors (HIFs) JO - J Clin Invest VL - 117 UR - https://doi.org/10.1172/JCI31370 DO - 10.1172/JCI31370 ID - Peyssonnaux2007 ER - TY - JOUR AU - Hasuike, Y. AU - Nonoguchi, H. AU - Tokuyama, M. AU - Ohue, M. AU - Nagai, T. AU - Yahiro, M. PY - 2010 DA - 2010// TI - Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study JO - Clin Exp Nephrol VL - 14 UR - https://doi.org/10.1007/s10157-010-0288-x DO - 10.1007/s10157-010-0288-x ID - Hasuike2010 ER - TY - JOUR AU - Karaboyas, A. AU - Morgenstern, H. AU - Pisoni, R. L. AU - Raymond Vanholder, J. Z. AU - Jacobson, S. H. AU - Inaba, M. PY - 2018 DA - 2018// TI - Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study JO - Nephrol Dial Transplant VL - 33 UR - https://doi.org/10.1093/ndt/gfy190 DO - 10.1093/ndt/gfy190 ID - Karaboyas2018 ER - TY - JOUR AU - Hamano, T. AU - Fujii, N. AU - Hayashi, T. AU - Yamamoto, H. AU - Iseki, K. AU - Tsubakihara, Y. PY - 2015 DA - 2015// TI - Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry JO - Kidney Int Suppl VL - 5 UR - https://doi.org/10.1038/kisup.2015.6 DO - 10.1038/kisup.2015.6 ID - Hamano2015 ER - TY - JOUR AU - Shoji, T. AU - Niihata, K. AU - Fukuma, S. AU - Fukuhara, S. AU - Akizawa, T. AU - Inaba, M. PY - 2017 DA - 2017// TI - Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation JO - Clin Exp Nephrol VL - 21 UR - https://doi.org/10.1007/s10157-016-1317-1 DO - 10.1007/s10157-016-1317-1 ID - Shoji2017 ER - TY - JOUR AU - Robinson, B. M. AU - Bieber, B. AU - Pisoni, R. L. AU - Port, F. K. PY - 2012 DA - 2012// TI - Dialysis Outcomes and Practice Patterns Study (DOPPS): its strengths, limitations, and role in informing practices and policies JO - Clin J Am Soc Nephrol VL - 7 UR - https://doi.org/10.2215/CJN.04940512 DO - 10.2215/CJN.04940512 ID - Robinson2012 ER - TY - STD TI - Maruyama Y, Yokoyama K, Yokoo T, Shigematsu T, Iseki K, Tsubakihara Y. The different association between serum ferritin and mortality in hemodialysis ans peritoneal dialysis patients using Japanese nationwide dialysis survey. PLoS One. 10(11):e0143430. https://doi.org/10.1371/journal.pone.0143430. ID - ref55 ER - TY - JOUR AU - Mursu, J. AU - Robien, K. AU - Harnack, L. J. AU - Park, K. AU - Jacobs, D. R. PY - 2011 DA - 2011// TI - Dietary supplements and mortality rate in older women: the Iowa Women’s Health Study JO - Arch Intern Med VL - 171 UR - https://doi.org/10.1001/archinternmed.2011.445 DO - 10.1001/archinternmed.2011.445 ID - Mursu2011 ER - TY - JOUR AU - Rostoker, G. AU - Griuncelli, M. AU - Loridon, C. AU - Magna, T. AU - Machado, G. AU - Drahi, G. PY - 2015 DA - 2015// TI - Reassessment of iron marker for prediction of dialysis iron overload: an MRI study JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0132006 DO - 10.1371/journal.pone.0132006 ID - Rostoker2015 ER - TY - JOUR AU - Ogawa, C. AU - Tsuchiya, K. AU - Tomosugi, N. AU - Kanda, F. AU - Maeda, K. AU - Maeda, T. PY - 2017 DA - 2017// TI - Low levels of serum ferritin and moderate transferrin saturation leads to adequate hemoglobin levels in hemodialysis patients, retrospective observational study JO - PLos ONE VL - 12 UR - https://doi.org/10.1371/journal.pone.0179608 DO - 10.1371/journal.pone.0179608 ID - Ogawa2017 ER - TY - JOUR AU - Anraku, M. AU - Kitamura, K. AU - Shintomo, R. AU - Takeuchi, K. AU - Ikeda, H. AU - Nagano, J. PY - 2008 DA - 2008// TI - Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study JO - Clin Biochem. VL - 41 UR - https://doi.org/10.1016/j.clinbiochem.2008.07.007 DO - 10.1016/j.clinbiochem.2008.07.007 ID - Anraku2008 ER - TY - JOUR AU - Yamamoto, H. AU - Nishi, S. AU - Tomo, T. AU - Masakane, I. AU - Saito, K. AU - Nangaku, M. PY - 2017 DA - 2017// TI - 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease JO - Ren Rep Ther VL - 3 ID - Yamamoto2017 ER - TY - JOUR AU - Macdougall, I. C. AU - White, C. AU - Anker, S. D. AU - Bhandari, S. AU - Farrington, K. AU - Kalra, P. A. PY - 2019 DA - 2019// TI - Intravenous iron in patients undergoing maintenance hemodialysis JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1810742 DO - 10.1056/NEJMoa1810742 ID - Macdougall2019 ER - TY - JOUR AU - Macdougall, I. C. AU - Bhandari, S. AU - White, C. AU - Anker, S. D. AU - Farrington, K. AU - Kalra, P. A. PY - 2020 DA - 2020// TI - Intravenous iron dosing and infection risk in hemodialysis patients: a pre-specified secondary analysis of the PIVOTAL trial JO - J Am Soc Nephrol VL - 31 UR - https://doi.org/10.1681/ASN.2019090972 DO - 10.1681/ASN.2019090972 ID - Macdougall2020 ER - TY - JOUR AU - Coyne, D. W. AU - Fishbane, S. PY - 2020 DA - 2020// TI - The value of intravenous iron: beyond the cave of speculation JO - J Am Soc Nephrol VL - 31 UR - https://doi.org/10.1681/ASN.2019121340 DO - 10.1681/ASN.2019121340 ID - Coyne2020 ER - TY - JOUR AU - Kuo, K. L. AU - Hung, S. C. AU - Tseng, W. C. AU - Tsai, M. T. AU - Liu, J. S. AU - Lin, M. H. PY - 2018 DA - 2018// TI - Association of anemia and iron parameters with mortality among patients undergoing prevalent hemodialysis in Taiwan: the AIM - HD study JO - J Am Heart Assoc VL - 7 UR - https://doi.org/10.1161/JAHA.118.009206 DO - 10.1161/JAHA.118.009206 ID - Kuo2018 ER - TY - JOUR AU - Winkelmayer, W. C. AU - Liu, J. AU - Brookhart, M. A. PY - 2009 DA - 2009// TI - Altitude and all-cause mortality in incident dialysis patients JO - JAMA VL - 301 UR - https://doi.org/10.1001/jama.2009.84 DO - 10.1001/jama.2009.84 ID - Winkelmayer2009 ER - TY - JOUR AU - Gupta, N. AU - Wish, J. B. PY - 2017 DA - 2017// TI - Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD JO - Am J Kidney Dis VL - 69 UR - https://doi.org/10.1053/j.ajkd.2016.12.011 DO - 10.1053/j.ajkd.2016.12.011 ID - Gupta2017 ER - TY - JOUR AU - Yeh, T. Z. AU - Leissing, T. M. AU - Abboud, M. I. AU - Thinnes, C. C. AU - Atasoylu, O. AU - Holt-Martyn, J. P. PY - 2017 DA - 2017// TI - Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials JO - Chem Sci VL - 8 UR - https://doi.org/10.1039/C7SC02103H DO - 10.1039/C7SC02103H ID - Yeh2017 ER - TY - STD TI - Tsubakihara Y, Akizawa T, Nangaku M, Onoue T, Yonekawa T, Matsushita H, et al. A 24-week anemia correction study of daprodustat in Japanese dialysis patients. Therapeutic Apheresis Dialysis. 2019. https://doi.org/10.1111/1744-9987.12962. ID - ref68 ER - TY - JOUR AU - Akizawa, T. AU - Nangaku, M. AU - Yonekawa, T. AU - Okuda, N. AU - Kawamatsu, S. AU - Onoue, T. PY - 2020 DA - 2020// TI - Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial JO - Clin J Am Soc Nephrol VL - 15 UR - https://doi.org/10.2215/CJN.16011219 DO - 10.2215/CJN.16011219 ID - Akizawa2020 ER - TY - JOUR AU - Hara, K. AU - Takahashi, N. AU - Wakamatsu, A. AU - Caltabiano, S. PY - 2015 DA - 2015// TI - Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects JO - Drug Metab Pharmacokinet VL - 30 UR - https://doi.org/10.1016/j.dmpk.2015.08.004 DO - 10.1016/j.dmpk.2015.08.004 ID - Hara2015 ER - TY - JOUR AU - Akizawa, T. AU - Iwasaki, M. AU - Otsuka, T. AU - Reusch, M. AU - Misumi, T. PY - 2019 DA - 2019// TI - roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial JO - Adv Ther VL - 36 UR - https://doi.org/10.1007/s12325-019-00943-4 DO - 10.1007/s12325-019-00943-4 ID - Akizawa2019 ER - TY - STD TI - Akizawa T, Ueno M, Shiga T, Reusch M. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: results from two phase 3 studies. Ther Apher Dial. 2019. https://doi.org/10.1111/1744-9987.13468 [Epub ahead of print]. ID - ref72 ER - TY - STD TI - Akizawa T, Otsuka T, Reusch M, Ueno M. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study. Ther Apher Dial 2020;24(2):115-125. doi: https://doi.org/10.1111/1744-9987.12888. Epub 2019 Jul 31. ID - ref73 ER - TY - JOUR AU - Chen, N. AU - Hao, C. AU - Liu, B. C. AU - Lin, H. AU - Wang, C. AU - Xing, C. PY - 2019 DA - 2019// TI - Roxadustat treatment for anemia in patients undergoing long-term dialysis JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1901713 DO - 10.1056/NEJMoa1901713 ID - Chen2019 ER - TY - JOUR AU - Akizawa, T. AU - Macdougall, I. C. AU - Berns, J. S. AU - Bernhardt, T. AU - Staedtler, G. AU - Taguchi, M. PY - 2019 DA - 2019// TI - Long-term efficacy and safety of Molidustat for anemia in chronic kidney disease: DIALOGUE extension studies JO - Am J Nephrol VL - 49 UR - https://doi.org/10.1159/000499111 DO - 10.1159/000499111 ID - Akizawa2019 ER - TY - JOUR AU - Akizawa, T. AU - Macdougall, I. C. AU - Berns, J. C. AU - Yamamoto, H. AU - Taguchi, M. AU - Iekushi, K. PY - 2019 DA - 2019// TI - Ion regulation by Molidustat, a daily oral hypoxia inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease JO - Nephron VL - 143 UR - https://doi.org/10.1159/000502012 DO - 10.1159/000502012 ID - Akizawa2019 ER - TY - STD TI - Akizawa T, Hanaki K, Arai M. JTZ-951 an oral novel HIF-PHD inhibitor, elevates hemoglobin in Japanese anemic patients with chronic kidney disease receiving maintenance hemodiaysis. 52nd ERA-EDTA. London; 2015. ID - ref77 ER - TY - JOUR AU - Zhong, H. AU - Zhou, T. AU - Li, H. AU - Zhong, Z. PY - 2018 DA - 2018// TI - The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease JO - Drug Des Devel Ther VL - 12 UR - https://doi.org/10.2147/DDDT.S175887 DO - 10.2147/DDDT.S175887 ID - Zhong2018 ER - TY - JOUR AU - Haase, V. H. PY - 2017 DA - 2017// TI - HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism JO - Hemodial Int VL - 21 UR - https://doi.org/10.1111/hdi.12567 DO - 10.1111/hdi.12567 ID - Haase2017 ER - TY - STD TI - Roxadustat phase III programme pooled analyses showed positive efficacy and no increases cardiovascular risk in patients with anaemia from chronic kidney disease. http://www.astrazeneca.co./mediacentre/press-release/2019/rozadustat-phase-iii-programme-pooled-analyse-showed-positive-efficacy-and-no-increased-cv-risk-in-patients-with-anaemia-from-chronic-kidney-disease.html. (Accessed June 15, 2020). ID - ref80 ER - TY - JOUR AU - Sanghani, N. S. AU - Hasse, V. H. PY - 2019 DA - 2019// TI - Hypoxia-inducible factor activators in renal anemia: current clinical experience JO - Adv Chronic Kidney Dis VL - 26 UR - https://doi.org/10.1053/j.ackd.2019.04.004 DO - 10.1053/j.ackd.2019.04.004 ID - Sanghani2019 ER - TY - JOUR AU - Flamme, I. AU - Oehme, F. AU - Ellinghaus, P. AU - Jeske, M. AU - Keldenich, M. AU - Thuss, U. PY - 2014 DA - 2014// TI - Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects JO - Plos One November VL - 9 UR - https://doi.org/10.1371/journal.pone.0111838 DO - 10.1371/journal.pone.0111838 ID - Flamme2014 ER - TY - BOOK AU - Uchida, K. AU - Nangaku, M. AU - Abe, M. AU - Okada, H. AU - Takeda, N. AU - Hanafusa, N. PY - 2020 DA - 2020// TI - Recommendation on the appropriate use of HIF-PH inhibitors: Japanese Society of Nephrology ID - Uchida2020 ER - TY - STD TI - Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita H, Nangaku M, et al. Prevalence of anemia in patients with chronic kidney disease in Japan: a nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (JCKD-DB). Plos One. 2020;15(7):e0236132. https://doi.org/10.1371/journal.pone.0236132. ID - ref84 ER -